Latest Content

The Importance of Personalized Treatment Approaches for Urologic Cancers

May 6th 2025, 7:00pm

By Ryan Scott

Article

Dr. Armine Smith discusses the importance of personalized therapeutic approaches for the treatment of urologic cancers, such as bladder or kidney cancer.

Nurse’s Big Personality Makes Cancer Treatment More Bearable.

May 6th 2025, 5:00pm

By Kelly Irvin

Article

She wore a variety of bright sneakers and occasionally did a cha-cha-cha in them. Her laughter was contagious. Patients smiled. The other nurses smiled.

Givinostat Wins U.S. FDA Fast Track Designation for Patients With PV

May 6th 2025, 4:00pm

By Ryan Scott

Article

Treatment with givinostat has received fast track designation from the United States Food and Drug Administration for patients with polycythemia vera.

First Patient With Advanced Lung Cancer Dosed With Peluntamig Combo

May 6th 2025, 3:00pm

By Spencer Feldman

Article

The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer and neuroendocrine carcinomas.

Delving Into the Braftovi Plus Erbitux FDA Approval for BRAF+ mCRC

May 6th 2025, 1:00pm

By Ryan Scott

Article

Dr. Cathy Eng discusses data that led to the FDA approval of Braftovi and Erbitux plus chemo for metastatic colorectal cancer with a BRAF V600E mutation.

A Staunch Advocate For Radiation Oncology Nursing and Compassionate Care

May 5th 2025, 9:00pm

By ALLISON OCHOCKI, B.S.N., RN

Article

Everyone knows someone who has been affected by cancer.

A Personalized Approach to Bladder Preservation in Urologic Cancers

May 5th 2025, 8:00pm

By Dr. Armine Smith

Video

Bladder preservation for bladder cancer requires balancing clinical factors and patient health with a personalized treatment plan.

Mitigating Peripheral Neuropathy During Cancer Treatment

May 5th 2025, 7:00pm

By Dr. Shirley D'Sa

Video

Dr. Shirley D'Sa discusses the importance of catching peripheral neuropathy in patients with Waldenström macroglobulinemia early on and how to treat it.

My Lung Cancer Journey: With Family, Friends and Medical Professionals

May 5th 2025, 5:00pm

By Sue McCarthy

Article

The strongest connections I’ve made are with others who have also been through their own cancer journeys.

AI Tool Predicts Pediatric Glioma Recurrence With Up to 89% Accuracy

May 5th 2025, 4:00pm

By Spencer Feldman

Article

An AI model using serial brain scans predicted glioma recurrence in children with up to 89% accuracy, outperforming single-image methods.

Exploring a Patient Case: Biomarker Testing After Progression and Discussing Treatment Choices With Your Care Team

May 5th 2025, 3:04pm

By Virginia Kaklamani, MD, DSc

Video

Panelists discuss how to communicate genomic testing results to patients and make shared treatment decisions, particularly when multiple targeted therapy options are available for patients with ESR1 and PIK3CA mutations.

First-Line Keytruda Combo Elicits OS Results in Head and Neck Cancers

May 5th 2025, 3:00pm

By Ryan Scott

Article

First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and neck squamous cell carcinoma.

Navigating Treatment After Progression: Testing, ESR1 Mutations and Tolerable Options

May 5th 2025, 3:00pm

By Virginia Kaklamani, MD, DSc

Video

Panelists discuss how to approach second-line therapy decisions for patients with metastatic breast cancer, emphasizing the importance of biomarker testing, including ESR1 mutations, and considering patient-specific factors.

Cancer Survivor Raises AYA Awareness After Rare Lymphoma Diagnosis

May 5th 2025, 1:00pm

By Spencer Feldman

Article

In this Q&A, Carly Stafford Dixon discusses her lymphoma journey, recovery with CAR T therapy, and mission to raise support for young adults with cancer.

POIESIS Trial Explores Navtemadlin Plus Jakafi for Myelofibrosis

May 5th 2025, 12:00pm

By Ryan Scott

Article

The phase 3 POIESIS trial is set to investigate navtemadlin as an add-on therapy to Jakafi in patients with JAK inhibitor-naive myelofibrosis.